Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR 1,766.45
+27.90 (1.60%)
At close: Apr 16, 2026
Caplin Point Laboratories Market Cap
Caplin Point Laboratories has a market cap or net worth of 134.27 billion as of April 16, 2026. Its market cap has decreased by -13.94% in one year.
Market Cap
134.27B
Enterprise Value
125.29B
Revenue
20.92B
Ranking
n/a
PE Ratio
21.94
Stock Price
1,766.45
Market Cap Chart
Since February 26, 2002, Caplin Point Laboratories's market cap has increased from 5.60M to 134.27B, an increase of 2,398,022.17%. That is a compound annual growth rate of 51.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 134.27B | -4.06% |
| Dec 31, 2025 | 139.95B | -26.39% |
| Dec 31, 2024 | 190.12B | 84.60% |
| Dec 29, 2023 | 102.99B | 90.47% |
| Dec 30, 2022 | 54.07B | -16.82% |
| Dec 31, 2021 | 65.01B | 69.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 408.24B |
| J. B. Chemicals & Pharmaceuticals | 320.90B |
| AstraZeneca Pharma India | 217.95B |
| Granules India | 156.79B |
| Jubilant Pharmova | 141.32B |
| Rubicon Research | 135.05B |
| CORONA Remedies | 96.47B |
| Viyash Scientific | 89.82B |